| Business Summary | | Nastech
Pharmaceutical
Company
Inc.
is
engaged
in
the
research,
development
and
manufacture
of
nasally
administered
prescription
pharmaceuticals.
Although
the
oral
route
of
drug
delivery
may
be
the
most
popular
and
least
expensive
method
of
delivery,
gastrointestinal
and
liver
metabolism
can
reduce
an
oral
drug's
effectiveness.
Generally,
a
nasal
delivery
system
will
provide
faster
absorption
into
the
blood
stream
than
an
oral
product,
thereby
resulting
in
faster
onset
of
action.
The
Company
has
a
commercial
interest
in
two
nasal
drug
products,
both
of
which
are
approved
for
sale
in
the
United
States.
Its
licensee
Bristol-Myers
Squibb
Company
markets
Stadol
NSTM
(Butorphanol
Tartrate),
and
its
licensee
Schwarz
Pharma
Inc.
markets
Nascobal
(Cyanocobalamin,
USP).
In
addition
to
these
two
drugs,
the
Company
has
several
drugs
in
various
stages
of
drug
research
and
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NSTK
is
engaged
in
the
research,
development,
manufacturing
and
commercialization
of
nasally
administered
forms
of
pharmaceuticals
that
are
currently
delivered
in
oral,
injectable
or
other
dosage
forms.
For
the
six
months
ended
6/30/01,
revenues
fell
20%
to
$1.7
million.
Net
loss
fell
1%
to
$4.4
million.
Revenues
reflect
a
decline
in
royalty
income
from
BMS
on
sales
of
Stadol
NS.
Lower
loss
reflects
lower
R&D,
royalty,
market
research
and
compensation
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Steven Quay, M.D., Ph.D., 50 Chairman,
Pres, CEO | $136K | Andrew Zinzi, 54 CFO | 199K | David Wormuth, 55 Sr.
VP | -- | Joel Girsky, 61 Treasurer,
Director | -- | Carol Wenig, 56 Sec. | 118K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|